ABT–874 is a fully human, monoclonal antibody directed against an inflammatory cytokine known as IL-12. IL-12 is a known mediator of inflammation and may be important in Crohn’s disease. Given the inflammatory nature of Crohn’s, many targets related to immune system function are being pursued. Already, approved infliximab targets the tumor necrosis factor, another member of the class of inflammatory cytokines. We have assigned ABT-874 a score of 60 for innovation status.

Crohn’s disease is a chronic, inflammatory disease of the gastrointestinal tract that affects between 500,000 and 1 million Americans. Usually diagnosed before age 30, symptoms include diarrhea, cramping, abdominal pain, weight loss, fever, and in some cases rectal bleeding. There is no cure for Crohn’s disease. Incidence estimates for this disease vary greatly, ranging from 1/100, 000 cases per year to 70/100, 000. Published studies seem to cluster around the 5-10/100, 000 range resulting in a burden of illness score of 10.

We have scored the demand/diffusion variable at 10 resulting in an overall BioHorizon Emerging Health Technology Impact Score of 30, placing ABT-874 in our Low Impact Technology category. No preliminary assessment activities are required at present.

Technology Details
Target Disease / Indication: Crohn’s Disease
Technology Classification: Drug
Body System: Gastrointestinal
Program Area: Medicine/Gastroenterology
Regulatory Status: Phase 2
BioHorizon Impact Score: 30/100 – Low

Humira is a human monoclonal antibody that is thought to exert its effect by interfering with the function of an inflammatory cytokine known as tumor necrosis factor alpha (TNF-a). TNF-a is thought to play a critical role in mediating the immune response that causes the signs and symptoms of rheumatoid arthritis and other autoimmune diseases. Humira is given subcutaneously by injection every two weeks. Other currently existing treatments for rheumatoird arthritis include Enbrel®, and Remicade® (both TNF-a biological response modifiers) and Amgen’s Kineret® (an Interleukin-1 inhibitor), all of which are relatively new.

Rheumatoid arthritis is a chronic autoimmune disease that causes pain and swelling of the joints and may progress to the point of joint destruction. It has been estimated that the incidence of rheumatoid arthritis in the United States is 70/100, 000 per year, with 1 to 2 % of the population ultimately affected.

Biohorizon has currently assigned Humira to the High Impact Technology category. At approximately $1200 per patient per month, it produces a significant cost increase when compared to the traditional disease modifying anti-rheumatic drugs such as methotrexate. Based on Abbott’s own reported and predicted sales numbers, diffusion seems to be occurring at an impressive rate. Biohorizon reiterates the need for health services organizations to plan for the continued and increased presence of Humira in rheumatoid arthritis treatment regimens.

Technology Details
Target Disease / Indication
Rheumatoid Arthritis

Technology Classification
Drug

Body System
Musculoskeletal System

Program Area
Medicine/Rheumatology

Regulatory Status
Approved

BioHorizon Impact Score
67/100 – High